Wednesday, December 28, 2016

Merck’s Ebola Vaccine Found to Protect Against Deadly Virus according to : bloomberg

This was collected by Lucy William

We will quote to you the news of the best health sites Like : "bloomberg" and the most famous medical experts : Natasha Khan


daily : 2016-12-28 & on time : 17:11


according to





Merck's Ebola Vaccine Found to Protect Against Deadly Virus


Merck's Ebola Vaccine Found to Protect Against Deadly Virus
image uploaded by "bloomberg" site
An experimental Ebola vaccine manufactured by Merck & Co. was found to be highly protective against the deadly virus, showing promise in the fight against future outbreaks after an earlier epidemic killed thousands and highlighted a shortage of weapons to battle the disease.The vaccine was studied in a trial involving more than 11,000 people in Guinea.Of those who received the shot in a final-stage trial, no Ebola cases were recorded after a ten-day incubation period, according to a study published in the medical journal, the Lancet.
about the details read more from here


Ebola Experimental Vaccine Provides 'Substantial Protection' Against Virus


Ebola Experimental Vaccine Provides 'Substantial Protection' Against Virus
image uploaded by "newsweek" site
An experimental vaccine against the Ebola virus, which has killed more than 11,000 people in West Africa since 2014, has shown great promise in protecting against the deadly disease.In a trial led by the World Health Organization (WHO), almost 6,000 people in Guinea—where the recent outbreak began in 2014—received the rVSV-ZEBOV vaccine, along with an equal-sized group that were not vaccinated.After 10 days, none of the vaccinated group had developed the virus.
about the details read more from here


Ebola Vaccine Gives 100 Percent Protection Against Common Strain of Virus


Ebola Vaccine Gives 100 Percent Protection Against Common Strain of Virus
image uploaded by "gizmodo" site
Image: GettyA new Ebola vaccine provides 100 percent protection against one of the two most common strains of the Ebola virus.The results of this trial were released in The Lancet on Thursday.Although the vaccine—known as rVSV-ZEBOV—has yet to be approved by regulators, the New York Times reports that scientists have already created an emergency supply of 300,000 doses, should another Ebola outbreak occur.
about the details read more from here


To follow all the new news about

VIRUSES and INFECTIONS

No comments:

Post a Comment